The flu vaccines for the 2022/2023 season go well with the flu pathogens that are actually already rampant. US scientists have recently proven this in laboratory tests. This means that there is still a good chance of being vaccinated once morest influenza.
A corresponding lead time is required for the production of the vaccines. That is why the production is always dependent on the recommendations of the World Health Organization (WHO) for the use of the antigens of certain influenza A and influenza B antigens for the vaccines of the coming flu season.
By no means always does each of the mostly four antigen components in the vaccines (two for influenza A, two for influenza B viruses) “fit” perfectly with the pathogens that are actually rampant. This leads to lower protection rates.
For 2022/2023, all people who want to protect themselves once morest the flu can most likely rely on the vaccines. That’s according to the December 2 influenza surveillance report from the US Centers for Disease Control.
